A database of FDA approved therapeutic peptides and proteins
Details of Th1217 which contains 1 entries. |
| Entry 1 | |
| (1) Primary information | |
|---|---|
| ID | 1827 |
| ThPP ID | Th1217 |
| Therapeutic Peptide/Protein Name | Anti-inhibitor coagulant complex |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 4-7 hours |
| Description | Anti-inhibitor coagulant complex is a freeze-dried sterile human plasma fraction with factor VIII inhibitor bypassing activity to be reconstituted for intravenous administration. Anti-inhibitor coagulant complex contains mainly non-activated factors II, IX, and X and mainly activated factor VII. It is manufactured from large pools of human plasma. |
| Indication/Disease | Controlling bleeding episodes or bleeding during surgery in patients who have hemophilia A or B with inhibitors. |
| Pharmacodynamics | Multiple interactions of the components in anti-inhibitor coagulant complex restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor. |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | Blood Coagulation Factors, Antihemophilic Agent |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). Avoid combination |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Feiba Nf |
| Company | NA |
| Brand Discription | Feiba NF is a clotting factor. It works by correcting the clotting defect, which allows blood clots to form. |
| Prescribed for | Controlling bleeding episodes or bleeding during surgery in patients who have hemophilia A or B with inhibitors. It should not be used to treat patients with other bleeding disorders. |
| Chemical Name | NA |
| Formulation | NA |
| Physcial Appearance | Solid |
| Route of Administration | Intravenous |
| Recommended Dosage | 50-100 units/kg per dose (maximum: 100 units/kg [single dose], 200 units/kg/day [total daily dose]). Dosage and duration of treatment depend on the location and extent of bleeding and clinical condition of the patient. |
| Contraindication | Known anaphylactic or severe hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation, including factors of the kinin generating system; disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction) |
| Side Effects | chest pain or discomfort |
| Useful Link | http://www.feiba.com/us/forms/feiba_nf_pi.pdf , https://www.drugs.com/cdi/anti-inhibitor-coagulant-complex.html |
| PubMed ID | 6777002 |
| 3-D Structure | N.A. |